Amorfix Life Sciences Ltd. (AMF) - Product Pipeline Analysis

Amorfix Life Sciences Ltd. (AMF) - Product Pipeline Analysis

Aug 2012 GlobalData Market Guide37 Pages Price :
$ 750

Amorfix Life Sciences Ltd. (Amorfix) is a theranostics company engaged in developing therapeutic products and diagnostic devices for treatment of brain-wasting diseases such as Amyotrophic Lateral Sclerosis (ALS), Alzheimers disease, Parkinsons disease and variant Creutzfeldt Jakob disease (vCJD). The company intends to develop diagnostic kits, biologic therapeutics, drug therapeutics, and prophylactics, such as vaccines for the treatment of aggregated misfolded proteins (AMP). Its lead programs include a diagnostic blood screening test for vCJD and a therapy for ALS. Amorfix has collaborated with BioMosaics Inc, a privately-held cancer biomarker development company, to develop and commercialize a blood-based assay for the early detection of hepatocellular carcinoma (HCC) or primary liver cancer. The company is headquartered in Mississauga, Ontario, Canada.

This report is a source for data, analysis and actionable intelligence on the Amorfix Life Sciences Ltd. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalDatas team of industry experts.

Scope

  • Detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
  • Detailed coverage on all the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
  • Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
  • Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
  • Data on relevant clinical trials and product patent details, wherever applicable.
  • Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
  • Design and develop your product development, marketing and sales strategies.
  • Exploit M&A opportunities by identifying market players with the most innovative pipeline.
  • Develop market-entry and market expansion strategies.
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Develop competition strategies by identifying the status and likely launch of your competitors pipeline products through review of the clinical trials, stage and phase of development, etc.
  • Which are the next high-value products that your competitor would add in its portfolio? identify, understand and capitalize.
Table of Content

Table of Contents 2
List of Tables 3
List of Figures 4
Amorfix Life Sciences Ltd. - Business Description 5

Key Facts 6
Amorfix Life Sciences Ltd. - Major Products and Services 7
Amorfix Life Sciences Ltd. Pipeline Products by Equipment Type 8
Amorfix Life Sciences Ltd. Pipeline Products by Development Stage 10
Amorfix Life Sciences Ltd. Pipeline Products by Therapy Area 12
Amorfix Life Sciences Ltd. Pipeline Products by Trial Phase 14
Amorfix Life Sciences Ltd. Pipeline Products by Milestone Summary 16
Diagnostic Blood Test - ALS 18
Diagnostic Blood Test - ALS Product Status 18
Diagnostic Blood Test - ALS Product Description 18
Diagnostic Blood Test - ALS Product Milestone 19
EP-AD Diagnostic CSF Test 20
EP-AD Diagnostic CSF Test Product Status 20
EP-AD Diagnostic CSF Test Product Description 20
EP-AD Diagnostic CSF Test Product Milestone 20
EP-AD Diagnostic CSF Test Clinical Trial 21
EP-AD Diagnostic CSF Test Product Patent Details 22
Product Institution Details 23
ProMIS - Cancer 24
ProMIS - Cancer Product Status 24
ProMIS - Cancer Product Description 24
ProMIS - Misfolded Protein Diseases 25
ProMIS - Misfolded Protein Diseases Product Status 25
ProMIS - Misfolded Protein Diseases Product Description 25
Screening Test - Liver Cancer 26
Screening Test - Liver Cancer Product Status 26
Screening Test - Liver Cancer Product Description 26
Screening Test - Liver Cancer Product Milestone 27
Product Institution Details 27
Amorfix Life Sciences Ltd. - Key Competitors 28
Amorfix Life Sciences Ltd. - Key Employees 29
Amorfix Life Sciences Ltd. - Key Employee Biographies 30
Amorfix Life Sciences Ltd. - Locations And Subsidiaries 31
Head Office 31
Recent Developments 32
Amorfix Life Sciences Ltd., Recent Developments 32
Jun 21, 2012: Amorfix Life Sciences Reports Fiscal 2012 Results 32
May 15, 2012: Amorfix Announces Development Of Antibodies That Bind To Misfolded Fas Receptor Protein As Potential Treatment For Cancer 32
Apr 04, 2012: Amorfix Establishes Proof Of Concept Of Tumor-Specific Antibody For Treatment Of Ovarian Cancer 32
Feb 23, 2012: Amorfix Appoints Lynda Covello As Vice President Of Strategic Alliances 33
Feb 10, 2012: Amorfix Life Sciences Reports Q3 Fiscal 2012 Results 33
Nov 14, 2011: Amorfix Life Sciences Reports Q2 Fiscal 2012 Results 34
Sep 13, 2011: Amorfix Life Sciences Reports Q1 Fiscal 2012 Results 34
Sep 09, 2011: Amorfix Appoints Meryl Chertoff To Board 35
Aug 11, 2011: Amorfix Provides Update On PreClinical Cancer Antibody Projects 36
Jun 29, 2011: Amorfix Life Sciences Reports Q4 Fiscal 2011 36

Appendix 37
Methodology 37
About GlobalData 37
Contact Us 37
Disclaimer 37

List of Table


Amorfix Life Sciences Ltd., Key Facts 1
Amorfix Life Sciences Ltd. Key Pipeline Products by Equipment Type 1
Amorfix Life Sciences Ltd. Key Pipeline Products by Therapy Area 1
Amorfix Life Sciences Ltd. Key Pipeline Products by Development Stage 1
Amorfix Life Sciences Ltd. Key Pipeline Products by Trial Phase 1
Amorfix Life Sciences Ltd., Key Facts 6
Amorfix Life Sciences Ltd., Major Products and Services 7
Amorfix Life Sciences Ltd. Number of Pipeline Products by Equipment Type 8
Amorfix Life Sciences Ltd. Pipeline Products by Equipment Type 9
Amorfix Life Sciences Ltd. Number of Pipeline Products by Development Stage 10
Amorfix Life Sciences Ltd. Pipeline Products by Development Stage 11
Amorfix Life Sciences Ltd. Number of Pipeline Products by Therapy Area 12
Amorfix Life Sciences Ltd. Pipeline Products by Therapy Area 13
Amorfix Life Sciences Ltd. Number of Pipeline Products by Trial Phase 14
Amorfix Life Sciences Ltd. Pipeline Products by Trial Phase 15
Amorfix Life Sciences Ltd. Number of Pipeline Products By Milestone Summary 16
Amorfix Life Sciences Ltd. Pipeline Products by Milestone Summary 17
Diagnostic Blood Test - ALS - Product Status 18
Diagnostic Blood Test - ALS - Product Description 18
Diagnostic Blood Test - ALS - Product Milestone 19
EP-AD Diagnostic CSF Test - Product Status 20
EP-AD Diagnostic CSF Test - Product Description 20
EP-AD Diagnostic CSF Test - Product Milestone 20
EP-AD Diagnostic CSF Test - Efficacy Study Of Amorfix AD Diagnostic Assay To Accurately Identify Patients With Alzheimers Disease 21
EP-AD Diagnostic CSF Test - Patent Details1 22
EP-AD Diagnostic CSF Test - Patent Details2 23
ProMIS - Cancer - Product Status 24
ProMIS - Cancer - Product Description 24
ProMIS - Misfolded Protein Diseases - Product Status 25
ProMIS - Misfolded Protein Diseases - Product Description 25
Screening Test - Liver Cancer - Product Status 26
Screening Test - Liver Cancer - Product Description 26
Screening Test - Liver Cancer - Product Milestone 27
Amorfix Life Sciences Ltd., Key Employees 29
Amorfix Life Sciences Ltd., Key Employee Biographies 30

List of Chart


Amorfix Life Sciences Ltd. Pipeline Products by Equipment Type 8
Amorfix Life Sciences Ltd. Pipeline Products by Development Stage 10
Amorfix Life Sciences Ltd. Pipeline Products by Therapy Area 12
Amorfix Life Sciences Ltd. Pipeline Products by Trial Phase 14
Amorfix Life Sciences Ltd. Pipeline Products by Milestone Summary 16

Ask for discount before buying this report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Your Requirement
  • Security Code *
* denotes fields which must be completed

Buy This Report


Select License Type :

$ 750
$ 1500

Do you wish to check sample of this report?

Have Query?


Research Assistance

For Enquiries, Call :

+1-800-998-4852US Toll Free

Email : sales@marketresearchhub.com

Back To Top